Eli Lilly reported strong sales growth for its drugs Mounjaro, Jaypirca, and Omvoh, with Jaypirca sales up 56.4% year-on-year to $192 million in Q2 despite competition. The company’s Retatrutide showed promising results in obesity trials, potentially setting a new market standard if FDA approved. Consequently, Eli Lilly raised its 2026 revenue guidance from $82-$85 billion to $85-$87 billion. These positive developments led ALLKA Research to upgrade Eli Lilly’s stock rating from Hold to Buy, reflecting confidence in its growth prospects.
Vanguard's VTSAX mutual fund, though low-cost on paper, can incur significant hidden expenses like capital gains taxes, a $3,000 minimum investment, and transaction fees outside Vanguard platforms. Its ETF counterpart, VTI, offers the same broad US m...
Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include ...
Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, accusing Lilly of misleading advertising about their weight-loss drug efficacy. Novo argues that Lilly's ads compare Lilly's Zepbound to an older, lower-dose version of ...
Novo Nordisk CEO Mike Doustdar highlighted the early stage of GLP-1 drug adoption for obesity treatment, noting that over 100 million Americans suffer from obesity but only about 10-15% have used these medications. He emphasized the potential for the...
Novo Nordisk has received a "Sell" rating due to growing competition from Eli Lilly and internal challenges like expiring patents and manufacturing issues. An analyst set a cautious price target of $47, reflecting concerns over flat to negative growt...
